Seminars in Oncology
Volume 34, Issue 2 , Pages 98-109, April 2007

Urinary Diversion: Options, Patient Selection, and Outcomes

  • Dipen J. Parekh
  • ,
  • S. Machele Donat

      Affiliations

    • Corresponding Author InformationAddress correspondence to S. Machele Donat, MD, FACS, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Improved survival following radical cystectomy for bladder cancer as a result of advancements in combination chemotherapy and surgical technique has resulted in a philosophical change in the surgeon’s approach to urinary diversion selection. Aims have evolved from the mere diversion of urine to a functional bowel conduit such as an ileal conduit or ureterosigmoidostomy, to providing the optimal diversion for the patient’s quality of life. While quality of life is important, one must also consider the stage of cancer and individual patient comorbidities. Which diversion provides the best local cancer control, the lowest potential for complications (short and long term), and the easiest emotional adjustment in lifestyle while still allowing the timely completion of chemotherapy and therapeutic goals? A multidisciplinary approach to diversion selection that includes the patient, the medical oncologist, radiation oncologist, internist, and surgeon is ideal. We describe the three most commonly used types of diversions today, including conduits, continent cutaneous reservoirs, and orthotopic urethral diversions, as well as issues relative to patient selection and functional outcomes in patients undergoing radical cystectomy for the treatment of bladder cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(06)00487-8

doi:10.1053/j.seminoncol.2006.12.010

Seminars in Oncology
Volume 34, Issue 2 , Pages 98-109, April 2007